Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| aTyr Pharma Inc. | Efzofitimod - (EFZO-FIT) | Pulmonary sarcoidosis | Phase 3 | Data Released | Intravenous | Respiratory |
| aTyr Pharma Inc. | Efzofitimod - (EFZO-CONNECT) | Systemic sclerosis (SSc)-associated interstitial lung disease (ILD) | Phase 2 | Data Released | Intravenous | Respiratory |
| Aura Biosciences Inc. | Bel-sar (AU-011) - (CoMpass) | Indeterminate lesions (ILs) and choroidal melanoma (CM) | Phase 3 | Data Released | Intravitreal injection | Oncology |
| Aura Biosciences Inc. | AU-011 (belzupacap sarotalocan) (IVT administration) - (CoMpass) | Uveal melanoma including choroidal melanoma | Phase 2 | Data Released | intravitreal | Oncology |
| Aurinia Pharmaceuticals Inc | Voclosporin - (VOCAL-EXT) | Pediatric Lupus Nephritis | Phase 3 | Ongoing | Oral | Immunology |
| Aurinia Pharmaceuticals Inc | Voclosporin - (VOCAL) | Pediatric Lupus Nephritis | Phase 3 | Ongoing | Oral | Immunology |
| Aurinia Pharmaceuticals Inc | Voclosporin ophthalmic solution (VOS) - AUDREY | Dry eye syndrome | Phase 2/3 | Trial Discontinued | Topical | Opthalmic |
| Avalo Therapeutics Inc. | AVTX-803 - (LADDER) | Leukocyte Adhesion Deficiency Type II (LAD II) | Phase 3 | Ongoing | Oral | Genetic Disorder |
